Skip to main content
Premium Trial:

Request an Annual Quote

Robocall for Testing Fraud

A new robocall is offering free genetic testing for cancer or heart disease as part of a scam to defraud Medicare, the Pittsburgh Post-Gazette reports.

The callers, the Post-Gazette adds, are after people's Medicare information so they can bill the government agency for fake or unneeded tests. In addition to scamming Medicare out of money and driving up costs, Rebecca Kinney from the US Department of Health and Human Services tells the Post-Gazette that scam victims could later face problems if they do need genetic testing, as it might look like they already had it.

"If you haven’t had a discussion with your doctor about needing these tests, hang up the phone," Kinney adds at the paper, further suggesting that prospective victims also report the encounter.

Similar schemes were reported in 2019 in which fraudsters set up tables at events senior citizen might frequent or went door-to-door to obtain individuals' Medicare information. Other schemers claimed to be from states' Medicaid programs and targeted homeless individuals by offering cash for a DNA swab. Additionally, another version of the scam in early 2020 offered COVID-19 testing.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.